Three VPC publications describe potential new therapeutics

Date Posted: 
2017-09-13

Thee publications out of the VPC describing work towards the development of new therapeutics were published in the last week.

A study led by Drs. Michael Cox, Artem Cherkasov, and Paul Rennie is featured in a Sept. 6th news story from the Terry Fox Research Institute. Published in Oncotarget, the work describes a first-in-class small molecule targeting the DNA binding domain of the ETS-family transcription factor, ERG. The study shows that that disrupting ERG transcriptional activity is sufficient to suppress the major characteristics of ERG-transformed prostate cancers; this finding could help develop new therapeutic tools for men battling ERG-expressing metastatic castration-resistant prostate cancer.

A study led by Dr. Gleave is featured in a Sept. 11th Publications of the Week post by Science in the City.  The European Urology publication describes the evaluation of the novel drug darolutamide in preclinical models of prostate cancer and found that darolutamide delays growth of enzalutamide-resistant prostate cancer, in particular in cells with mutated forms of the androgen receptor after previous treatment. This data supports further evaluation of darolutamide in clinical trials.

A study lead by Dr. Zoubeidi was published on Sept. 12 in Clinical Cancer Research online. In this preclinical study, the group investigated molecular targets and therapeutics for PCS1, the most aggressive and lethal subtype of prostate cancer. They report that the Forkhead box M1 (FOXM1) pathway is the central driver of this subtype in enzalutamide castration-resistant prostate cancer, and targeting FOXM1 reduces cell growth and stemness. These preclinical results may guide clinical evaluation of targeting FOXM1 to eradicate highly aggressive and lethal PCS1 prostate cancer tumours.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Rock4Prostate

Rock4Prostate fundraiser - Friday Nov 8, 2019

The 2nd annual Rock4Prostate event takes place Friday Nov 8 at the Backstage Lounge Pub on Granville Island.  Tickets available at Eventbrite and at the door ($20 or $10 for students 19+), with proceeds going to Prostate Cancer Canada.  Please visit the Facebook event page for more details

VPC Movember 2013 team

Movember fundraiser: Nov. 1 - 30, 2019

Movember is an international charity raising funds for men's health initiatives. Movember Canada focuses on prostate cancer, testicular cancer, mental health and suicide prevention. Please visit moteam.co/the-vancouver-prostate-centre to join or donate to our Centre's Movember fundraising team.

Employment

Work at the Vancouver Prostate Centre

Monday, September 16, 2019

Drs Cox, Gleave and Goldenberg awarded Prostate Cancer Canada and Movember 2019 Discovery Grants

Drs Cox, Gleave and Goldenberg
Thursday, September 12, 2019

Drs. Wyatt and Sorensen receive 2019 UBC Faculty of Medicine Awards for Distinguished Achievement

Drs Wyatt and Sorensen
Tuesday, September 10, 2019

Drs. Sorensen, Ester and Huntsman elected to Royal Society of Canada

Drs Sorensen, Ester, Huntsman